Overview

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.

Phase:

Phase 2

Details

Lead Sponsor:

Enyo Pharma

Collaborators:

Eurofins
Novotech (Australia) Pty Limited
Parexel
Synteract, Inc.

Treatments:

Entecavir
Tenofovir